Dr. Romano received his PhD. in Molecular Biology and Biochemistry from Wesleyan University and was an Adjunct Scientist and Post-Doctoral Fellow at the NIH (NICHD) in the lab of National Academy of Sciences member Alan Hinnebusch. He has held positions at Thomas Jefferson University and Drexel University Medical School, where he established research programs leading to the discovery of serum biomarkers (GP73) and the creation of molecular reagents used in licensed diagnostic assays (Glycotest Diagnostics) for the early detection of liver disease and hepatocellular carcinoma. As Director of Molecular Pharmacology at Nucleonics Inc. (IP acquired by Alnylam Pharmaceuticals) he developed a pre-clinical safety and toxicology program which enabled an IND filing for the first in human trials of an eiRNA based therapeutic drug directed against Hepatitis B Virus (HBV).  Most recently, at FlowMetric Diagnostics, Dr. Romano created and developed the VaxEffect Serology Assay, for use in the detection of COVID-19 exposure and vaccination response in individuals.